» Articles » PMID: 16862521

An External Quality Assessment Program for Von Willebrand Factor Laboratory Analysis: an Overview from the European Concerted Action on Thrombosis and Disabilities Foundation

Overview
Publisher Thieme
Date 2006 Jul 25
PMID 16862521
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The laboratory diagnosis of von Willebrand disease (vWD) is complex and requires a panel of different laboratory tests. Because of this complexity, a proper quality control process is necessary. Since 2003, the European Concerted Action on Thrombosis and Disabilities Foundation has provided an external quality control program for several laboratory tests included in the diagnosis of vWD. Currently, ~180 different laboratories participate in this program, of which the vast majority perform both von Willebrand factor (vWF):antigen (Ag) and activity tests. The lowest between-laboratory variation was observed for the vWF antigen assay (10 to 24%), with a better performance for the latex immunoassay (8 to 24%) than the enzyme immunoassay (13 to 25%). Both the ristocetin cofactor activity assay (RCo) and the collagen-binding assay showed a higher between-laboratory variation (20 to 40% and 17 to 29%, respectively). We have observed that the within-laboratory repeatability for normal samples ranged from 0 to 40% for the antigen assay and from 0 to 86% for the ristocetin cofactor activity assay. Normal samples were interpreted correctly by the majority of the participants. However, type 1 vWD samples were wrongly interpreted by 20 to 40% of the participants, which was mainly caused by a discordance in the vWF:RCo/vWF:Ag ratio. It can be concluded that further improvement in the laboratory diagnosis of vWD is necessary.

Citing Articles

Conformation-specific RNA aptamers for phenotypic distinction between normal von Willebrand factor and type 2B von Willebrand disease.

Machha V, Tischer A, Moon-Tasson L, Tange J, Santiago-Davis A, Pruthi R NAR Mol Med. 2024; 1(4):ugae021.

PMID: 39719968 PMC: 11664255. DOI: 10.1093/narmme/ugae021.


Gastrointestinal Angiodysplasia Resolution After Transcatheter Aortic Valve Implantation.

Goltstein L, Rooijakkers M, Thierens N, Schoormans S, van Herwaarden A, Beaumont H JAMA Netw Open. 2024; 7(10):e2442324.

PMID: 39476231 PMC: 11525602. DOI: 10.1001/jamanetworkopen.2024.42324.


Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD.

Roberts J, Christopherson P, Tarantino M, Gonzales S, Morateck P, Perry C Haemophilia. 2023; 30(1):161-168.

PMID: 38013388 PMC: 10842138. DOI: 10.1111/hae.14901.


Establishing reference intervals for von Willebrand factor multimers.

Pikta M, Vasse M, Smock K, Moser K, van D, Lejniece S J Med Biochem. 2022; 41(1):115-121.

PMID: 35431650 PMC: 8970582. DOI: 10.5937/jomb0-31941.


Obstacles to Early Diagnosis and Treatment of Inherited von Willebrand Disease: Current Perspectives.

Castaman G, Linari S J Blood Med. 2021; 12:165-175.

PMID: 33790680 PMC: 7997550. DOI: 10.2147/JBM.S232758.